Healio (5/27, Gramigna) reports, “Esketamine nasal spray appeared to rapidly reduce depressive symptoms among severely ill patients with major depressive disorder [MDD] who had active suicidal ideation with intent,” investigators concluded in the 226-patient, “double-blind, randomized phase 3 ASPIRE I study,” the findings of which were published online in the Journal of Clinical Psychiatry (SOURCE: APA Headlines)
- ) strategy and implementation of activities aimed at increased supports for caregivers of persons with mental illness, in addition to the continued work of the Coalition and sustaining the collaboration between aging and behavioral health providers at the local level.
- Studies Support Effectiveness Of Ketamine, Esketamine For Difficult-To-Treat Depression, MDD With Suicidal Ideation, Expert Says
- In Small Study, Investigational Nondopamine Antipsychotic Show Signals It May Improve Psychosis Symptoms In Patients With Parkinson’s Disease
- Benzoate Treatment Appears To Improve Cognitive Function Among Women With Later-Stage Dementia In Small Study
- More Than One In Ten Patients Who Receive An ICD May Also Develop Anxiety Or Depression, Research Suggests